Analyst Price Target is $17.00
▲ +421.47% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Checkpoint Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $18.00 and a low forecast of $16.00. The average price target represents a 421.47% upside from the last price of $3.26.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Checkpoint Therapeutics. This Buy consensus rating has held steady for over two years.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in New York, NY.